Company profile

2seventy bio, Inc. (wholly-owned subsidiary of Bristol Myers Squibb)

Privately held: no public share price (Formerly Nasdaq: TSVT. Bristol Myers Squibb completed an all-cash acquisition on 2025-05-13; 2seventy bio was delisted from Nasdaq the same day and now operates as a wholly-owned BMS subsidiary (SEC Form 8-K/SC 14D9; investing.com merger-completion coverage). No longer separately public. Sources: https://clinicaltrials.gov/study/NCT03274219 Entity resolved by asset-pipeline-v2.)

Assets

(1 total)
1Total Assets
0Approved
0Phase 3 / Filed
1Phase 1–2 / Early
1Diseases
Showing 1 of 1 assets
Target & Modality
bb21217No recent activity
Phase 1
BCMACell therapy
Multiple Myeloma

Upcoming events

Research

Unlock the company readout calendar

Research includes estimated primary-completion dates, earnings report dates, and 'What to watch' trial analysis across this company’s pipeline.

Financial reports

Research

Unlock sourced financial history

Research includes quarterly, interim and annual revenue, R&D, cash and burn figures linked to the underlying company reports.

Educational data tool. Figures are sourced from company filings and press releases: see each row's filing link. Share price is delayed (~15min) and refreshed periodically, not a real-time feed.